PL2441466T3 - Środek hamujący MIC-1 - Google Patents

Środek hamujący MIC-1

Info

Publication number
PL2441466T3
PL2441466T3 PL11183884T PL11183884T PL2441466T3 PL 2441466 T3 PL2441466 T3 PL 2441466T3 PL 11183884 T PL11183884 T PL 11183884T PL 11183884 T PL11183884 T PL 11183884T PL 2441466 T3 PL2441466 T3 PL 2441466T3
Authority
PL
Poland
Prior art keywords
mic
inhibiting agent
inhibiting
agent
Prior art date
Application number
PL11183884T
Other languages
English (en)
Inventor
Samuel Norbet Breit
Asne Rhoda Bauskin
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2441466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of PL2441466T3 publication Critical patent/PL2441466T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL11183884T 2004-04-13 2005-04-13 Środek hamujący MIC-1 PL2441466T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP11183884.3A EP2441466B1 (en) 2004-04-13 2005-04-13 MIC-1 inhibiting agent
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
PL2441466T3 true PL2441466T3 (pl) 2015-01-30

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15163748T PL2929891T3 (pl) 2004-04-13 2005-04-13 Sposób modulowania apetytu
PL11183884T PL2441466T3 (pl) 2004-04-13 2005-04-13 Środek hamujący MIC-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15163748T PL2929891T3 (pl) 2004-04-13 2005-04-13 Sposób modulowania apetytu

Country Status (11)

Country Link
US (7) US8192735B2 (pl)
EP (4) EP1734986B1 (pl)
JP (4) JP5448338B2 (pl)
CA (2) CA2561877C (pl)
CY (1) CY1115731T1 (pl)
DK (2) DK2929891T3 (pl)
ES (3) ES2518865T3 (pl)
PL (2) PL2929891T3 (pl)
PT (2) PT2441466E (pl)
SI (1) SI2441466T1 (pl)
WO (1) WO2005099746A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2518865T3 (es) * 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
WO2008015254A2 (en) * 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
JP5444363B2 (ja) * 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
PT2900263T (pt) 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15)
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
UA116665C2 (uk) 2013-07-31 2018-04-25 Емджен Інк. Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
EP3122775B1 (en) * 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
MX2016016826A (es) 2014-06-20 2017-08-28 Aveo Pharmaceuticals Inc Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.
SG11201609706VA (en) * 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN106459222A (zh) 2014-06-24 2017-02-22 诺和诺德股份有限公司 Mic‑1融合蛋白及其用途
TN2016000578A1 (en) * 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
HUE054670T2 (hu) * 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP2018502908A (ja) * 2014-12-22 2018-02-01 ノヴォ ノルディスク アー／エス アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用
JP6925326B2 (ja) 2015-10-02 2021-08-25 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
JP6858181B2 (ja) 2015-10-02 2021-04-14 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108700573B (zh) * 2016-02-29 2021-06-11 公立大学法人横滨市立大学 检测去势抵抗性前列腺癌的方法和检测试剂
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
MA46523A (fr) * 2016-10-12 2019-08-21 Janssen Biotech Inc Procédés de criblage de modulateurs d'une activité biologique de type gdf15
CA3045700A1 (en) * 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
CA3109905A1 (en) 2018-08-20 2020-02-27 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
US11055575B2 (en) 2018-11-13 2021-07-06 CurieAI, Inc. Intelligent health monitoring
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
KR20210065057A (ko) 2019-11-26 2021-06-03 주식회사유한양행 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
IL302646A (en) 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022245179A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
EP4351628A4 (en) 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT
EP4384545A1 (en) 2021-08-10 2024-06-19 BYOMass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
AU1103900A (en) 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins
EP1914554B1 (en) 2000-04-20 2010-06-09 St Vincent's Hospital Sydney Limited Diagnostic assay involving macrophage inhibitory cytokine-1 (MIC-1)
WO2002020759A2 (en) * 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2518865T3 (es) 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
PT1844337E (pt) * 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE

Also Published As

Publication number Publication date
US8946146B2 (en) 2015-02-03
DK2441466T3 (da) 2014-10-27
PT2441466E (pt) 2014-09-09
US20090004181A1 (en) 2009-01-01
JP2011190262A (ja) 2011-09-29
US20250109192A1 (en) 2025-04-03
JP5448338B2 (ja) 2014-03-19
JP5767667B2 (ja) 2015-08-19
US20150183861A1 (en) 2015-07-02
EP1734986A4 (en) 2009-07-22
HK1215932A1 (en) 2016-09-30
JP2007532586A (ja) 2007-11-15
US20110123454A1 (en) 2011-05-26
CA2561877C (en) 2017-03-14
PT2929891T (pt) 2020-04-08
US20180346560A1 (en) 2018-12-06
EP2441466A1 (en) 2012-04-18
EP1734986B1 (en) 2015-11-11
EP2929891A1 (en) 2015-10-14
US20210340243A1 (en) 2021-11-04
ES2518865T3 (es) 2014-11-05
DK2929891T3 (da) 2020-05-11
HK1168274A1 (en) 2012-12-28
EP2929891B1 (en) 2020-03-11
CA2561877A1 (en) 2005-10-27
PL2929891T3 (pl) 2020-08-24
ES2555956T3 (es) 2016-01-11
EP1734986A1 (en) 2006-12-27
US8192735B2 (en) 2012-06-05
EP2441466B1 (en) 2014-07-23
CA2905125A1 (en) 2005-10-27
EP2774620A1 (en) 2014-09-10
SI2441466T1 (sl) 2015-01-30
US20160289320A1 (en) 2016-10-06
JP2014051511A (ja) 2014-03-20
WO2005099746A1 (en) 2005-10-27
JP5806275B2 (ja) 2015-11-10
JP2013209376A (ja) 2013-10-10
CA2905125C (en) 2017-02-07
ES2788868T3 (es) 2020-10-23
CY1115731T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
PT2441466E (pt) Agente de inibição de mic-1
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
EG23651A (en) Culturama
DE602005010905D1 (en) Roboterhandvorrichtung
DE502005007040D1 (en) Laryngoskop
IL178033A0 (en) Herbicide-safener combination
DE602005008719D1 (en) Notinformationsschild
DE502004004685D1 (en) Giessmaschine
SI1811990T1 (sl) Sredstva proti demodikozi
ZA200606546B (en) Herbicide-safener combination
GB0406443D0 (en) Cast-cutter
DE502004004917D1 (en) Multiaxialkomplex
GB0413160D0 (en) Autopark
GB0409310D0 (en) Cancap
DE502005006813D1 (en) Common-rail-injektor
DE502005004945D1 (en) Auto-splice-system
GB0400310D0 (en) Anti-incrustation agent
GB0412633D0 (en) Portalock
PL368096A1 (pl) Środek zwilżająco-piorący
EP1712219A4 (en) AGENT DECREASING WRINKLES
IL165455A0 (en) Combination
GB0418486D0 (en) Dexx+ crum-buster
GB0400097D0 (en) Rolla-store
GB0416075D0 (en) Beeda-loo
GB0423157D0 (en) Hydrodechlorification